Three-Year Outcomes Reported by Patients Using Bimekizumab for Plaque Psoriasis: Findings from the BE RADIANT Randomized Trial - Summary - MDSpire

Three-Year Outcomes Reported by Patients Using Bimekizumab for Plaque Psoriasis: Findings from the BE RADIANT Randomized Trial

  • By

  • Matthias Augustin

  • Steven R. Feldman

  • Richard B. Warren

  • April Armstrong

  • Ronald Vender

  • Anna López-Ferrer

  • William H. Dawe

  • Jérémy Lambert

  • Balint Szilagyi

  • Bengt Hoepken

  • Rhys Warham

  • Alice B. Gottlieb

  • April 1, 2026

  • 0 min

Share

Objective:

To report long-term patient-reported outcomes (PROs) and their relationship with clinical outcomes in patients with moderate to severe plaque psoriasis treated with bimekizumab.

Key Findings:
  • Bimekizumab showed significant improvements in PROs over 3 years, with many patients reporting no symptoms of itching, skin pain, or scaling.
  • A substantial proportion of patients achieved DLQI scores indicating no or small effects on their quality of life.
  • Concurrent achievement of clinical and PRO outcomes was observed, indicating effective treatment.
Interpretation:

The findings suggest that bimekizumab not only improves clinical measures of psoriasis but also significantly enhances patients' quality of life, as reflected in PROs.

Limitations:
  • The study was a post hoc analysis, which may introduce biases.
  • Long-term follow-up data may not be generalizable to all psoriasis patients.
Conclusion:

Bimekizumab demonstrates sustained efficacy in improving both clinical outcomes and patient-reported quality of life in individuals with moderate to severe plaque psoriasis over three years.

Original Source(s)

Three-Year Outcomes Reported by Patients Using Bimekizumab for Plaque Psoriasis: Findings from the BE RADIANT Randomized Trial

  • by Matthias Augustin, Steven R. Feldman, Richard B. Warren, April Armstrong, Ronald Vender, Anna López-Ferrer, William H. Dawe, Jérémy Lambert, Balint Szilagyi, Bengt Hoepken, Rhys Warham, Alice B. Gottlieb

  • April 1, 2026

Related Content

Assessment of Tildrakizumab's Effectiveness and Safety in Patients with Moderate-to-Severe Plaque Psoriasis and Diabetes: Combined Analysis from reSURFACE 1 and reSURFACE 2 Trials

Biologics Tied to Lower Eye Risk in Psoriasis

Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.

The Role of SERPINA12 in Skin: Molecular Mechanisms and Its Involvement in Adipocyte Function, Psoriasis, and Palmoplantar Keratoderma